GSA Capital Partners LLP Acquires Shares of 11,811 Guardant Health, Inc. $GH

GSA Capital Partners LLP acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the second quarter, Holdings Channel.com reports. The firm acquired 11,811 shares of the company’s stock, valued at approximately $1,772,000.

Several other large investors have also made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new stake in Guardant Health in the 3rd quarter valued at $114,421,000. Price T Rowe Associates Inc. MD raised its position in Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after acquiring an additional 1,414,441 shares during the period. Norges Bank acquired a new position in Guardant Health during the fourth quarter worth $128,499,000. Summit Partners Public Asset Management LLC lifted its holdings in Guardant Health by 674.5% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock valued at $87,019,000 after purchasing an additional 741,958 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Guardant Health by 89.6% during the first quarter. The Manufacturers Life Insurance Company now owns 1,205,701 shares of the company’s stock valued at $111,371,000 after purchasing an additional 569,766 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GH has been the topic of several research analyst reports. Morgan Stanley lifted their target price on shares of Guardant Health from $175.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Royal Bank Of Canada raised their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Evercore reaffirmed an “outperform” rating and issued a $200.00 price target on shares of Guardant Health in a research note on Monday, July 6th. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, TD Cowen boosted their price objective on Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $183.78.

Insider Transactions at Guardant Health

In related news, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Chris Freeman sold 63,605 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the completion of the sale, the insider owned 65,374 shares of the company’s stock, valued at approximately $11,086,122.92. The trade was a 49.31% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 784,234 shares of company stock valued at $106,493,352. Company insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

Guardant Health stock opened at $157.21 on Monday. Guardant Health, Inc. has a 52-week low of $53.40 and a 52-week high of $176.58. The firm has a market capitalization of $21.10 billion, a price-to-earnings ratio of -45.05 and a beta of 1.60. The company has a fifty day simple moving average of $150.40 and a 200-day simple moving average of $116.89.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.